These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Topić E; Stefanović M; Samardzija M Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384 [TBL] [Abstract][Full Text] [Related]
3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP; Day CP; Kesteven PJ; Daly AK Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515 [TBL] [Abstract][Full Text] [Related]
5. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282 [TBL] [Abstract][Full Text] [Related]
6. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971 [TBL] [Abstract][Full Text] [Related]
7. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]. Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349 [TBL] [Abstract][Full Text] [Related]
9. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin]. Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757 [TBL] [Abstract][Full Text] [Related]
10. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972 [TBL] [Abstract][Full Text] [Related]
11. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893 [TBL] [Abstract][Full Text] [Related]
12. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573 [TBL] [Abstract][Full Text] [Related]
13. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464 [TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population. Siddiqi A; Khan DA; Khan FA; Naveed AK Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456 [TBL] [Abstract][Full Text] [Related]
15. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9. Lee SY; Kim JS; Kim JW Yonsei Med J; 2005 Dec; 46(6):843-6. PubMed ID: 16385662 [TBL] [Abstract][Full Text] [Related]
16. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846 [TBL] [Abstract][Full Text] [Related]
17. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol]. Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670 [TBL] [Abstract][Full Text] [Related]
18. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement. Lee SY; Nam MH; Kim JS; Kim JW J Korean Med Sci; 2007 Jun; 22(3):557-9. PubMed ID: 17596671 [TBL] [Abstract][Full Text] [Related]
19. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. King BP; Khan TI; Aithal GP; Kamali F; Daly AK Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560 [TBL] [Abstract][Full Text] [Related]
20. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Lima MV; Ribeiro GS; Mesquita ET; Victer PR; Vianna-Jorge R Eur J Clin Pharmacol; 2008 Jan; 64(1):9-15. PubMed ID: 17955230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]